Open AccessProgressive plasmacytoid variant bladder cancer with retroperitoneal dissemination: An autopsy case report
Author(s) -
Kohada Yuki,
Kaiho Yasuhiro,
Ito Jun,
Mikami Jotaro,
Anan Go,
Asano Katsutoshi,
Yaegashi Toru,
Murakami Kazuhiro,
Nakamura Yasuhiro,
Sato Makoto
Publication year - 2020
Publication title -
iju case reports
Language(s) - English
Resource type - Journals
ISSN - 2577-171X
DOI - 10.1002/iju5.12167
Subject(s) - medicine , chemotherapy , gemcitabine , pembrolizumab , pathology , autopsy , metastasis , carcinoma , infiltration (hvac) , metastatic urothelial carcinoma , bladder cancer , oncology , cancer , urothelial carcinoma , immunotherapy , physics , thermodynamics
Plasmacytoid urothelial carcinoma is a rare and aggressive variant of bladder cancer. Case presentation A 75‐year‐old woman presented with plasmacytoid urothelial carcinoma with retroperitoneal dissemination was treated with chemotherapy. After an unsuccessful first‐line chemotherapy with gemcitabine and cisplatin, we assessed circulating tumor cells; one such cell was found to be positive for programmed death‐ligand 1. The patient received second‐line chemotherapy with pembrolizumab. However, the tumor extended to the retroperitoneal organs, and the patient eventually died. Autopsy revealed a widespread diffuse scirrhous infiltration of the carcinoma into the retroperitoneum. However, distant metastasis was not observed. Conclusion The evaluation of circulating tumor cells and autopsy revealed a disease state of progressive plasmacytoid urothelial carcinoma treated with pembrolizumab.